Workflow
奥锐特药业股份有限公司关于变更持续督导保荐代表人的公告

Core Viewpoint - The announcement details the change of the continuous supervision sponsor representative for Aorite Pharmaceutical Co., Ltd. due to the work change of the original representative, ensuring the orderly continuation of the supervision work [1][2]. Group 1: Change of Sponsor Representative - Aorite Pharmaceutical received a notice from Guotai Junan Securities regarding the replacement of the continuous supervision sponsor representative [1]. - The original representatives, Lin Zengjin and Wang Ziyang, were responsible for the supervision of the company's convertible bond issuance project, with Lin Zengjin being replaced by Pang Jun due to work changes [1][2]. - The new continuous supervision sponsor representatives for the 2024 convertible bond project are Wang Ziyang and Pang Jun [2]. Group 2: Convertible Bond Information - The company issued 812.12 million yuan worth of convertible bonds on July 26, 2024, with a maturity of six years and a face value of 100 yuan per bond [7]. - The initial conversion price for the bonds is set at 25.23 yuan per share, and the bonds can be converted into shares starting from February 5, 2025 [7]. - The bond's coupon rates increase progressively from 0.30% in the first year to 2.50% in the sixth year [7]. Group 3: Price Adjustment Conditions - The conditions for adjusting the conversion price are triggered if the company's stock price closes below 21.45 yuan (85% of the conversion price) for at least 15 out of 30 consecutive trading days [6][11]. - As of April 14, 2025, the stock price had already closed below the threshold for 10 trading days, indicating a potential for triggering the price adjustment [11]. - If the adjustment is triggered, the company will hold a board meeting to decide on the adjustment and will disclose the information accordingly [6][9].